Investor Resources
TaiMed Biologics is a publicly listed biotechnology company on the Taipei Exchange (TPEx: 4147). This section provides access to financial information, corporate governance materials, shareholder resources, sustainability information, and investor presentations.
TaiMed Biologics is a publicly listed biotechnology company on the Taipei Exchange (TPEx: 4147). This section provides access to financial information, corporate governance materials, shareholder resources, sustainability information, and investor presentations.
| Company Name | TaiMed Biologics, Inc. |
|---|---|
| Stock Name | TaiMed |
| Market Type | TPEX-Listed |
| Date Founded | 2007-09-05 |
| Date of Listing | 2015-11-23 |
| Code | 4147 |
| Listed Market | Taipei Exchange |
| Industry | Biotech |
| Core Business | New drug development for HIV |
| Chairman | Ming-Tsuen Chen |
| Major Shareholder | Ruentex group, National Development Fund |
| Paid-in Capital | NT$ 2,731,192,250 |
| Employees | 81 |
| PStock Transfer Institution | Shareholder Services Department, Taishin Securities Co., Ltd. |
| Auditors | Deloitte & Touch, Taipei |
| Bankers | Land Bank of Taiwan, Mega International Commercial Bank, E.Sun Bank |
| Legal Advisors | Formosan Brothers Attorneys-at-law |
| Address | 3F., No.607, Ruiguang Rd., Neihu Dist., Taipei City 11492, Taiwan |
| Telephone | +886-2-2658-0058 |
| Fax | +886-2-2658-6058 |
| ir@taimedbio.com | |
| Website | https://www.taimedbiologics.com/ |
Download file
Contact CDMO Service